Structural analysis of atovaquone-inhibited cytochrome bc 1 complex reveals the molecular basis of antimalarial drug action

Nature Communications

Volumn 5, Issue , 2014, Pages

  Birth, Dominic ^a   Kao, Wei Chun ^a   Hunte, Carola ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; CARBONYL DERIVATIVE; HYDROXYL GROUP; NAPHTHOQUINONE; NITROGEN; OXYGEN; UBIQUINOL CYTOCHROME C REDUCTASE; ANTIMALARIAL AGENT; PROTOZOAL PROTEIN; SACCHAROMYCES CEREVISIAE PROTEIN;

ANTIMALARIAL AGENT; CATALYSIS; CHEMICAL BONDING; CYTOCHROME; DRUG; MITOCHONDRION; MOLECULAR ANALYSIS; PARASITE; YEAST;

ABSORPTION; ABSORPTION SPECTROSCOPY; ARTICLE; CATALYSIS; CONSENSUS SEQUENCE; CONTROLLED STUDY; CRYSTALLIZATION; DISULFIDE BOND; DOSE RESPONSE; DRUG BINDING; DRUG CONFORMATION; DRUG DOSE TITRATION; DRUG MECHANISM; ENZYME ACTIVITY; HYDROGEN BOND; IC 50; LIGAND BINDING; LOW DRUG DOSE; MOLECULAR INTERACTION; NONHUMAN; PH; SACCHAROMYCES CEREVISIAE; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION; BINDING SITE; DRUG EFFECTS; METABOLISM; MITOCHONDRIAL MEMBRANE; MOLECULAR DOCKING; PLASMODIUM FALCIPARUM; SPECTROSCOPY; X RAY CRYSTALLOGRAPHY;

ANTIMALARIALS; ATOVAQUONE; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; ELECTRON TRANSPORT COMPLEX III; MITOCHONDRIAL MEMBRANES; MOLECULAR DOCKING SIMULATION; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; SEQUENCE ANALYSIS, PROTEIN; SPECTRUM ANALYSIS;

EID: 84902007671     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5029     Document Type: Article

References (60)

1. WHO. World Malaria Report 2012 Fact Sheet, http://www.who.int/malaria/ publications/world-malaria-report-2012/en/, 1-2 (2012).
2. Petersen, I., Eastman, R. &Lanzer, M. Drug-resistant malaria: molecular mechanisms and implications for public health. FEBS Lett. 585, 1551-1562 (2011).
3. Osei-Akoto, A., Orton, L. C. &Owusu-Ofori, S. Atovaquone-proguanil for treating uncomplicated malaria. Cochrane Database Syst. Rev. CD004529 (2005).
4. Lalloo, D. G. &Hill, D. R. Preventing malaria in travellers. BMJ 336, 1362-1366 (2008). (Pubitemid 351914627)
5. Laufer, M. K. et al. A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria. PLoS ONE 7, e42284 (2012).
6. Hudson, A. T. Atovaquone - a novel broad-spectrum anti-infective drug. Parasitol. Today 9, 66-68 (1993). (Pubitemid 23038653)
7. Araujo, F. G., Huskinson, J. &Remington, J. S. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob. Agents Chemother. 35, 293-299 (1991).
8. Hughes, L. M. et al. Design of anti-parasitic and anti-fungal hydroxynaphthoquinones that are less susceptible to drug resistance. Mol. Biochem. Parasitol. 177, 12-19 (2011).
9. Kovacs, J. A. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. Lancet 340, 637-638 (1992).
10. Fry, M. &Pudney, M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(40-chlorophenyl) cyclohexyl]-3-hydroxy- 1,4-naphthoquinone (566C80). Biochem. Pharmacol. 43, 1545-1553 (1992).
11. Hunte, C., Solmaz, S., Palsdottir, H. &Wenz, T. A structural perspective on mechanism and function of the cytochrome bc1 complex. Results Probl. Cell. Differ. 45, 253-278 (2008).
12. Barton, V., Fisher, N., Biagini, G. A., Ward, S. A. &O'Neill, P. M. Inhibiting Plasmodium cytochrome bc1: a complex issue. Curr. Opin. Chem. Biol. 14, 440-446 (2010).
13. Painter, H. J., Morrisey, J. M., Mather, M. W. &Vaidya, A. B. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature 446, 88-91 (2007). (Pubitemid 46348043)
14. Srivastava, I. K. &Vaidya, A. B. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob. Agents Chemother. 43, 1334-1339 (1999). (Pubitemid 29259321)
15. Srivastava, I. K., Rottenberg, H. &Vaidya, A. B. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J. Biol. Chem. 272, 3961-3966 (1997). (Pubitemid 27078454)
16. Hunte, C., Koepke, J., Lange, C., Rossmanith, T. &Michel, H. Structure at 2.3 angstrom resolution of the cytochrome bc(1) complex from the yeast Saccharomyces cerevisiae co-crystallized with an antibody Fv fragment. Struct. Fold Des. 8, 669-684 (2000). (Pubitemid 30409318)
17. Iwata, S. et al. Complete structure of the 11-subunit bovine mitochondrial cytochrome bc1 complex. Science 281, 64-71 (1998). (Pubitemid 28354043)
18. Xia, D. et al. Crystal structure of the cytochrome bc(1) complex from bovine heart mitochondria. Science 277, 60-66 (1997). (Pubitemid 27450644)
19. Zhang, Z. L. et al. Electron transfer by domain movement in cytochrome bc1. Nature 392, 677-684 (1998).
20. Crofts, A. R. in The Enyzmes of Biological Membranes (ed. Martonosi, A. N.) 347-382 (Plenum Publishing Corporation, 1985).
21. Mitchell, P. Possible molecular mechanisms of the protonmotive function of cytochrome c systems. J. Theor. Biol. 62, 327-367 (1976).
22. Osyczka, A., Moser, C. C. &Dutton, P. L. Fixing the Q cycle. Trends Biochem. Sci. 30, 176-182 (2005). (Pubitemid 40463306)
23. Zhang, Z. et al. Electron transfer by domain movement in cytochrome bc1. Nature 392, 677-684 (1998). (Pubitemid 28207780)
24. Palsdottir, H., Lojero, C. G., Trumpower, B. L. &Hunte, C. Structure of the yeast cytochrome bc1 complex with a hydroxyquinone anion Qo site inhibitor bound. J. Biol. Chem. 278, 31303-31311 (2003). (Pubitemid 36994649)
25. Kessl, J. J. et al. Molecular basis for atovaquone binding to the cytochrome bc1 complex. J. Biol. Chem. 278, 31312-31318 (2003). (Pubitemid 36994650)
26. Biagini, G. A. et al. Acridinediones: selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex. Mol. Pharmacol. 73, 1347-1355 (2008). (Pubitemid 351574824)
27. Nilsen, A. et al. Quinolone-3-diarylethers: a new class of antimalarial drug. Sci. Transl. Med. 5, 177ra37 (2013).
28. Wenz, T., Hellwig, P., MacMillan, F., Meunier, B. &Hunte, C. Probing the role of E272 in quinol oxidation of mitochondrial complex III. Biochemistry 45, 9042-9052 (2006). (Pubitemid 44156366)
29. Kessl, J. J., Meshnick, S. R. &Trumpower, B. L. Modeling the molecular basis of atovaquone resistance in parasites and pathogenic fungi. Trends Parasitol. 23, 494-501 (2007). (Pubitemid 47465093)
30. Fisher, N. et al. Cytochrome b mutation Y268S conferring the atovaquone resistance phenotype in the malaria parasite results in reduced parasite bc1 catalytic turnover and protein expression. J. Biol. Chem. 287, 9731-9741 (2012).
31. Nixon, G. L. et al. Antimalarial pharmacology and therapeutics of atovaquone. J. Antimicrob. Chemother. 68, 977-985 (2013).
32. Fisher, N. &Meunier, B. Re-examination of inhibitor resistance conferred by Q(o)-site mutations in cytochrome b using yeast as a model system. Pest Manag. Sci. 61, 973-978 (2005). (Pubitemid 41367962)
33. Korsinczky, M. et al. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob. Agents Chemother. 44, 2100-2108 (2000). (Pubitemid 30484433)
34. Fisher, N. &Meunier, B. Molecular basis of resistance to cytochrome bc1 inhibitors. FEMS Yeast Res. 8, 183-192 (2008). (Pubitemid 351208182)
35. Kessl, J. J. et al. Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc(1) complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae. J. Biol. Chem. 280, 17142-17148 (2005). (Pubitemid 41389179)
36. Kongkathip, N. et al. Transforming rhinacanthin analogues from potent anticancer agents into potent antimalarial agents. J. Med. Chem. 53, 1211-1221 (2010).
37. Fieser, L. F. et al. Naphthoquinone antimalarials; general survey. J. Am. Chem. Soc. 70, 3151-3155 (1948).
38. Trumpower, B. L. &Haggerty, J. G. Inhibition of electron transfer in the cytochrome b-c, segment of the mitochondrial respiratory chain by a synthetic analogue of ubiquinone. J. Bioenerg. Biomembr. 12, 151-164 (1980). (Pubitemid 11220311)
39. Solmaz, S. R. &Hunte, C. Structure of complex III with bound cytochrome c in reduced state and definition of a minimal core interface for electron transfer. J. Biol. Chem. 283, 17542-17549 (2008).
40. Lange, C. &Hunte, C. Crystal structure of the yeast cytochrome bc(1) complex with its bound substrate cytochrome c. Proc. Natl Acad. Sci. USA 99, 2800-2805 (2002). (Pubitemid 34240541)
41. Lan, W. X. et al. Conformational toggling of yeast iso-1-cytochrome c in the oxidized and reduced states. PLoS ONE 6, e27219 (2011).
42. Tsai, A. &Palmer, G. Potentiometric studies on yeast complex III. Biochim. Biophys. Acta 722, 349-363 (1983).
43. Link, T. A., Hagen, W. R., Pierik, A. J., Assmann, C. &von Jagow, G. Determination of the redox properties of the Rieske [2Fe-2S] cluster of bovine heart bc1 complex by direct electrochemistry of a water-soluble fragment. Eur. J. Biochem. 208, 685-691 (1992).
44. Lancaster, C. R. D., Hunte, C., Kelley, J., Trumpower, B. L. &Ditchfield, R. A comparison of stigmatellin conformations, free and bound to the photosynthetic reaction center and the cytochrome bc(1) complex. J. Mol. Biol. 368, 197-208 (2007). (Pubitemid 46441228)
45. Pruitt, K. D., Tatusova, T., Brown, G. R. &Maglott, D. R. NCBI reference sequences (RefSeq): current status, new features and genome annotation policy. Nucleic Acids Res. 40, D130-D135 (2012).
46. Sigrist, C. J. et al. PROSITE, a protein domain database for functional characterization and annotation. Nucleic Acids Res.38, D161-D166 (2010).
47. Johnson, L. S., Eddy, S. R. &Portugaly, E. Hidden Markov model speed heuristic and iterative HMM search procedure. BMC Bioinformatics 11, 431 (2010).
48. Sievers, F. et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 7, 539 (2011).
49. Fu, L., Niu, B., Zhu, Z., Wu, S. &Li, W. CD-HIT: accelerated for clustering the next-generation sequencing data. Bioinformatics 28, 3150-3152 (2012).
50. Nixon, G. L. et al. Antimalarial pharmacology and therapeutics of atovaquone. J. Antimicrob. Chemother. 68, 977-985 (2013).
51. Wenz, T. et al. Mutational analysis of cytochrome b at the ubiquinol oxidation site of yeast complex III. J. Biol. Chem. 282, 3977-3988 (2007). (Pubitemid 47084452)
52. Kazanjian, P. et al. Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS. J. Infect. Dis. 183, 819-822 (2001). (Pubitemid 32171759)
53. Hill, P. et al. Recapitulation in Saccharomyces cerevisiae of cytochrome b mutations conferring resistance to atovaquone in Pneumocystis jirovecii. Antimicrob. Agents Chemother. 47, 2725-2731 (2003). (Pubitemid 37040240)
54. Kabsch, W. Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
55. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
56. Emsley, P., Lohkamp, B., Scott, W. G. &Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
57. Schuttelkopf, A. W. &van Aalten, D. M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 60, 1355-1363 (2004). (Pubitemid 41079731)
58. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235-242 (2011).
59. Potterton, E., Briggs, P., Turkenburg, M. &Dodson, E. A graphical user interface to the CCP4 program suite. Acta Crystallogr. D Biol. Crystallogr. 59, 1131-1137 (2003). (Pubitemid 36872348)
60. Pettersen, E. F. et al. UCSF chimera - A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 (2004).